Literature DB >> 9144487

B7-blocking agents, alone or in combination with cyclosporin A, induce antigen-specific anergy of human memory T cells.

Z Yi-qun1, K Lorré, M de Boer, J L Ceuppens.   

Abstract

T cell anergy refers to a functional state in which the cells are alive but unable to produce IL-2 after appropriate triggering. Lack of CD28 costimulation through CD80 and CD86 molecules on APC might play a causative role in anergy induction, as previously shown with T cell clones. We now developed a model of anergy induction in cultures of freshly isolated memory T cells. Addition of either CTLA-4Ig or blocking anti-CD80 and anti-CD86 mAbs, in combination with cyclosporin A, to cultures of PBMC with soluble Ag consistently resulted in Ag-specific unresponsiveness, as evidenced upon antigenic rechallenge. In most experiments, the presence of cyclosporin A was not required, and blocking the B7-CD28 interaction during antigenic stimulation was sufficient to induce unresponsiveness. Unresponsiveness was apparent at the level of T cell proliferation as well as at the level of IL-2 and IFN-gamma production, and T cell responses to unrelated Ags were intact. Induction of unresponsiveness correlated with lack of T cell proliferation in the induction culture and could largely be prevented by supplementing the induction cultures with rIL-2, indicating that lack of IL-2 was responsible for this altered functional state. Unresponsive T cells did not suppress the proliferation of autologous T cells in response to original or third-party Ags. On the other hand, culture with IL-2 and Ag could reverse established T cell unresponsiveness, pointing to anergy rather than deletion as the underlying mechanism. Anergy induction in freshly isolated memory T cells opens perspectives for treatment of autoimmune and allergic diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9144487

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  10 in total

1.  Blocking B7 and CD40 co-stimulatory molecules decreases antiviral T cell activity.

Authors:  J Vermeiren; J L Ceuppens; H Haegel-Kronenberger; M De Boer; L Boon; S W Van Gool
Journal:  Clin Exp Immunol       Date:  2004-02       Impact factor: 4.330

Review 2.  Immunotherapy coming of age: what will it take to make it standard of care for glioblastoma?

Authors:  Amy B Heimberger; John H Sampson
Journal:  Neuro Oncol       Date:  2010-12-10       Impact factor: 12.300

3.  Preferential costimulation by CD80 results in IL-10-dependent TGF-beta1(+) -adaptive regulatory T cell generation.

Authors:  Nicolas Perez; Subha Karumuthil-Melethil; Ruobing Li; Bellur S Prabhakar; Mark J Holterman; Chenthamarakshan Vasu
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

4.  The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses.

Authors:  S Farzana Hussain; David Yang; Dima Suki; Kenneth Aldape; Elizabeth Grimm; Amy B Heimberger
Journal:  Neuro Oncol       Date:  2006-06-14       Impact factor: 12.300

5.  Decreased interferon-gamma (IFN-gamma)-producing T cells in patients with acute Kawasaki disease.

Authors:  T Matsubara; K Katayama; T Matsuoka; M Fujiwara; M Koga; S Furukawa
Journal:  Clin Exp Immunol       Date:  1999-06       Impact factor: 4.330

6.  miRNA-mediated immune regulation and immunotherapeutic potential in glioblastoma.

Authors:  Krishan Jethwa; Jun Wei; Kayla McEnery; Amy B Heimberger
Journal:  Clin Investig (Lond)       Date:  2011-12

Review 7.  The role of tregs in glioma-mediated immunosuppression: potential target for intervention.

Authors:  William Humphries; Jun Wei; John H Sampson; Amy B Heimberger
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

8.  Low concentrations of lipopolysaccharide synergize with peptides to augment human T-cell proliferation and can prevent the induction of non-responsiveness by CTLA4-Ig.

Authors:  M R Goodier; M Londei
Journal:  Immunology       Date:  2001-01       Impact factor: 7.397

9.  Monte Carlo cross-validation analysis screens pathway cross-talk associated with Parkinson's disease.

Authors:  Tianrong Li; Weidong Tang; Li Zhang
Journal:  Neurol Sci       Date:  2016-05-04       Impact factor: 3.307

Review 10.  Innate and adaptive immunity for the pathobiology of Parkinson's disease.

Authors:  David K Stone; Ashley D Reynolds; R Lee Mosley; Howard E Gendelman
Journal:  Antioxid Redox Signal       Date:  2009-09       Impact factor: 8.401

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.